ArticleCerebellum (London, England)2026
Listening in Spatialized Noise-Sentences (LiSN-S) as a Measure of Auditory Function in Friedreich Ataxia.
Article in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Auditory dysfunction is a clinically significant component of Friedreich ataxia (FRDA), but its features are not readily captured in standard audiology. We examined the Listening in Spatialized Noise–Sentences (LiSN-S) test as a measure of auditory function in a large cohort of subjects with this disease. Methods: We examined 101 individuals with FRDA with the LiSN -S, compared the results with 38 controls, and correlated results with disease features. Results. Control participants scored better than individuals with FRDA on all of the LiSN-S sub-scores. Correlations of LiSN-S scores with the Friedreich Ataxia Rating Scale (FARS) exams were moderate (0.5–0.7), while correlations were lower with genetic markers such as GAA1 and age of onset (0.32–0.54). Correlations were lower still with disease duration (0.25–0.29). Linear regressions to define the independent effects of age and GAA1 demonstrated that GAA1 uniformly predicted LiSN-S advantage scores (p < 0.01) but age predicted spatial advantage and total advantage ( P < 0.01) but not talker advantage. LiSN-S scores were slightly more affected in individuals with clinical auditory complaints. Conclusions: LiSN -S testing captures audiologic dysfunction in FRDA in a manner that appears to dependent on genetic severity and to a lesser degree time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.